CT-1 has been shown to promote insulin-stimulated glucose uptake in myotubes and cultured adipocytes [12], to modulate the production of other adipokines [26] and to exert protective effects against liver apoptosis [27], hepatocyte injury [28], hepatic steatosis [13] and renal damage [29]. Here, CTF1 is linked to fatty liver disease.